Evolus to Report Second Quarter 2020 Financial Results and Provide a Business Update on Monday, August 10, 2020

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS) announced it will report its second quarter 2020 financial results on August 10, 2020, after U.S. markets close. The company, known for its customer-centric approach and breakthrough products, will hold a conference call at 4:30 p.m. ET the same day to discuss the results. Dial-in details for the call are provided, along with a replay option available until August 17, 2020. Evolus is recognized for its FDA-approved neurotoxin Jeuveau^®, specifically targeting aesthetics.

NEWPORT BEACH, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2020 financial results and provide a business update on Monday, August 10, 2020 after the close of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question and answer session will follow management remarks.

The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers.  The conference ID is 7575816.

A replay of the call will be available following its completion through August 17, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 7575816.

A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.

About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau^® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.

Jeuveau^® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contact:
Ashwin Agarwal
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: IR@Evolus.com 

Media Contact:
Crystal Muilenburg
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: media@evolus.com 

FAQ

When will Evolus report its second quarter 2020 financial results?

Evolus will report its second quarter 2020 financial results on August 10, 2020, after the close of U.S. markets.

What time is the Evolus conference call scheduled for?

The Evolus conference call is scheduled for 4:30 p.m. ET on August 10, 2020.

How can I access the Evolus financial results conference call?

You can access the Evolus financial results conference call by dialing (866) 916-2317 for domestic callers or (703) 925-2662 for international callers.

Is there a replay available for the Evolus conference call?

Yes, a replay of the Evolus conference call will be available until August 17, 2020.

What is Jeuveau by Evolus?

Jeuveau^® is the first neurotoxin approved by the FDA specifically for aesthetic use, developed by Evolus.